State Street’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

State Street’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,434	Closed	-$12.7K	–	4752
2023 Q1	$12.7K	Hold	3,434	–	–	﹤0.01%	4730
2022 Q4	$13.1K	Hold	3,434	–	–	﹤0.01%	4779
2022 Q3	$27K	Hold	3,434	–	–	﹤0.01%	4783
2022 Q2	$72K	Hold	3,434	–	–	﹤0.01%	4642
2022 Q1	$129K	Buy	3,434 +533	+18%	+$18.4K	﹤0.01%	4557
2021 Q4	$163K	Hold	2,901	–	–	﹤0.01%	4429
2021 Q3	$209K	Buy	2,901 +1,710	+144%	+$131K	﹤0.01%	4340
2021 Q2	$114K	Sell	1,191 -11,715	-91%	-$1.29M	﹤0.01%	4334
2021 Q1	$1.91M	Buy	12,906 +136	+1%	+$24.6K	﹤0.01%	3456
2020 Q4	$1.78M	Sell	12,770 -1,112	-8%	-$180K	﹤0.01%	3409
2020 Q3	$2.11M	Buy	13,882 +1,442	+12%	+$235K	﹤0.01%	3177
2020 Q2	$2.18M	Buy	+12,440	New	+$2.08M	﹤0.01%	3148
2018 Q3	–	Sell	-26	Closed	-$2K	–	3809
2018 Q2	$2K	Hold	26	–	–	﹤0.01%	3767
2018 Q1	$2K	Hold	26	–	–	﹤0.01%	3752
2017 Q4	$20K	Hold	26	–	–	﹤0.01%	3691
2017 Q3	$7K	Hold	26	–	–	﹤0.01%	3753
2017 Q2	$6K	Hold	26	–	–	﹤0.01%	3688
2017 Q1	$8K	Hold	26	–	–	﹤0.01%	3648
2016 Q4	$16K	Hold	26	–	–	﹤0.01%	3622
2016 Q3	$30K	Hold	26	–	–	﹤0.01%	3513
2016 Q2	$29K	Hold	26	–	–	﹤0.01%	3631
2016 Q1	$33K	Hold	26	–	–	﹤0.01%	3639
2015 Q4	$64K	Hold	26	–	–	﹤0.01%	3581
2015 Q3	$29K	Sell	26 -2	-7%	-$2.32K	﹤0.01%	3626
2015 Q2	$28K	Sell	28 -613	-96%	-$661K	﹤0.01%	3652
2015 Q1	$655K	Buy	641 +97	+18%	+$320K	﹤0.01%	3317
2014 Q4	$1.81M	Buy	544 +36	+7%	+$110K	﹤0.01%	3082
2014 Q3	$1.47M	Buy	508 +14	+3%	+$46.3K	﹤0.01%	3139
2014 Q2	$1.88M	Buy	494 +465	+1,603%	+$1.75M	﹤0.01%	3090
2014 Q1	$158K	Buy	29 +1	+4%	+$5.27K	﹤0.01%	3479
2013 Q4	$89K	Hold	28	–	–	﹤0.01%	3493
2013 Q3	$92K	Buy	+28	New	+$76.3K	﹤0.01%	3470

Other funds holding NBSE

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

DCMIC

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

CMU

Carnegie Mellon University Pittsburgh, Pennsylvania $64.3M AUM 35.71% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street's NBSE Position: Q2 2023 in Review

State Street sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2023, closing a stake of 3,434 shares — an estimated $12.7K sold.

State Street first reported a position in NBSE in Q3 2013 and held it in 32 quarters. The position peaked at $2.18M in Q2 2020. 27 funds tracked by Wall St. Rank hold NBSE as of Q2 2023.

State Street reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
State Street sold 3,434 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $12.7K.
State Street first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q3 2013 and held it in 32 quarters.
State Street's NeuBase Therapeutics, Inc. Common Stock position peaked at $2.18M in Q2 2020.
27 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2023.

Based on State Street's 13F filing for Q2 2023, filed 14 Aug 2023.